Biofrontera (BFRI) Q4 2024 earnings summary

Executive summary

• Achieved record annual sales of $37.3 million in 2024, up 9.5% year-over-year, with Q4 sales growth of 18.5%, driven by Ameluz and RhodoLED XL lamp launches.

• Placed 100 RhodoLED XL lamps since June 2024 launch, supporting Ameluz PDT expansion and obtained FDA approval for expanded Ameluz use.

• Advanced clinical pipeline with significant progress in Phase 3 and Phase 2 studies, including completion of patient recruitment for label expansion.

• Restructured agreements with Biofrontera AG, reducing Ameluz transfer price from 50% to 25% for 2024 and 2025.

• Created Biofrontera Discovery GmbH to manage US clinical trials.

Financial highlights

• Q4 2024 revenues were $12.6 million, up 18.5% from Q4 2023; full-year revenues reached $37.3 million, up 9.5%.

• Q4 net loss was $1.4 million ($0.19/share) vs. net income of $3.5 million ($1.65/share) in Q4 2023, due to a prior-year legal settlement gain.

• Full-year net loss was $17.8 million ($3.22/share), improved from $20.1 million ($13.02/share) in 2023.

• Adjusted EBITDA for 2024 was negative $15.3 million, improved from negative $19.5 million in 2023; Q4 adjusted EBITDA was negative $1.4 million, improved from negative $3.2 million.

• Cash and cash equivalents at year-end 2024 were $5.9 million, up from $1.3 million at year-end 2023.

Outlook and guidance

• Anticipates another record sales year in 2025, supported by expanded product offerings, label extensions, and clinical progress.

• Expects gross margins to benefit in 2025 from the lower 25% transfer price for Ameluz.

• SG&A and R&D expenses projected to remain stable in 2025.

• Strategic focus for 2025 includes supporting current customers, improving PDT service efficiency, and expanding the customer base.